Rhythm Pharmaceuticals (RYTM) stock

Rare disease medicinesGLP-1 and obesity drugs

Market cap $6.4B

$93.44

+0.94%

Rare disease medicines, market cap $6.4BGLP-1 and obesity drugs

As of Monday's close · Live for Pro members at the open

Quality Score

Below Average

In its industry

#96of 291

Biotech

Checks firing

4of 14

Trending down

From 52-week high

-23.5%

Below the 200-day

RYTM's Quality Score rose 1 point on Mon, Nov 2, to 2.

Follow RYTM's trial news. Pro members can get an alert when Rhythm Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.

Get an alert when RYTM files news on its trialsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next2H 2026“…H2 2026 Complete enrollment in substudy evaluating setmelanotide in congenital hypothalamic obesity H2 2026…”Trial start · SEC filing · Aug 4

Cash$331M, about 12 quarters (3 years) at the last year's spendingOn Jun 30

Why is RYTM down?

Down 17% in a year while the S&P 500 rose 12%; up 307% over three years.

Revenue grew 45.8% a year against its 3 peers' median of 54.7%.

Sources: Price history, Oct 30, 2026; Annual reports, Dec 31, 2025; Peers' annual reports, Oct 30, 2026

How the business stands, the timeline, and its peers, for Pro members.

Key facts on RYTM

Key facts on RYTM
Holding it back	A $205M loss wider than $183M a year earlier
Latest filing	10-Q, Aug 4 Filed its quarterly report (10-Q) for the quarter to Jun 30, 2026

1 more reason behind RYTM's 2, free with an account →2 more reasons behind RYTM's 2, for Pro members.

RYTM in the news

ReportReports tomorrow, before the open. Every 3 months, a company tells everyone how much it sold and earned. It rose after 2 and fell after 2 of its last 4 reports, +0.5% on average. Past reports ›

What's next

Mon Nov 9: Guggenheim 3rd Annual Global…Investor conference · date confirmed.

1 more date ahead: the conference, for Pro members.

Cash$331M, about 12 quarters (3 years) at the last year's spendingOn Jun 30

RYTM catalysts

Coming up

After its last 4 reports it closed +0.5% on average, higher 2 of 4 times.

1 more coming up and 14 past catalysts since 2021, with sizes and sources, for Pro members.Get in free →

What's next for RYTM, and how long its cash lasts

Next step the company has named

2H 2026“…and Welfare (MHLW) H2 2026 Complete enrollment in substudy evaluating setmelanotide in congenital hypothalamic obesity H2 2026 Complete enrollment in the Ph1/2, Part D trial evaluating…”Trial start · SEC filing · Aug 4

What it means: when a trial begins, or reaches the stage the company named.

Lead program: Setmelanotide · Hypothalamic Obesity · Phase 3
Its trial: Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)Phase 3 · Recruiting · 39 people · main data estimated Mar 13, 2027 · NCT06760546

4 more trials, 40 filings, for Pro members.

Cash runway Jun 30 balance sheet

About 12 quarters

$331M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3ASR, filed Feb 26, 2026)
At-the-market share sales program (S-3ASR, filed Feb 26, 2026)

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

CEO David P Meeker sold 50,000 shares on Sep 14, under a planned sale. 11 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when David Meeker buys or sells

For Pro members: every trade, and David Meeker’s 19 filings and quotes.

Get an alert when RYTM files news on its trialsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 20 daysFDA decisionIn 20 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $385MDeramiocelFDA decision due (PDUFA)
In 20 daysFDA decisionIn 20 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $1.0BMolgramostimFDA decision due (PDUFA)
In 50 daysFDA decisionIn 50 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.9BLorundrostatFDA decision due (PDUFA)

11 more FDA dates and 102 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 143 dates, ranked →

Why RYTM scores 2

Below Averagefor quality, not price, 4 of 14 chart checks firingWhat the Quality Score means

+4Chart checks 4 of 14 firing right now, one point each
−2Long-term trend below a falling 200-⁠day average, down over one year

Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Growth addsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Run-up, Size, Dilution, Volatility, Persistence, and News.

What every line is worth, and the reason behind it, on RYTM and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 8:06 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

Alert me when RYTM's Quality Score turns up

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Here is what Pro members see.

The same page for Pro members, on AMD
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on RYTM and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

RYTM has 4 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on RYTM, and all 14 on every stock.Get in free →

RYTM RSI today: 52.6, below its 50-day and 200-day averages

Not scored

Not in the Quality Score: over 20 years of tests, 2006 to 2026, they added no edge.

RSI 1452.6
Above 50, below 70.
MACD (12, 26, 9)Above signal
Crossed above its signal line 9 sessions ago.
50-day average$96.85
The price is 3.5% below it.
200-day average$97.03
The price is 3.7% below it.
50/200 crossDeath cross
The 50-day crossed below the 200-day on Nov 2.
ADX 1425.4
25 or more, with +DI above -DI.
Support$87.19
Swing low from Mar 3, 6.7% below the price.
Resistance$93.50
Swing high from May 29, 0.1% above the price.
52-week high$122.20
From Dec 11, 2025, 30.8% above the price.
52-week low$74.50
From Mar 30, 20.3% below the price.
Chart patternNone
No triangle, channel, or wedge in the last year.
Bollinger Bands (20, 2)Inside
The bands run from $85.66 to $94.03.
Volume2.9x
Against its 20-day average, for the time of day.

The deep dive on RYTM

What it does and how it makes money4 findingsAn operating loss of $192M in fiscal 2025, on $190M of sales.Annual report, filed Feb 26, 2026"For example, in a key patent family providing composition of matter coverage for setmelanotide, we have received 5 years of patent term extension in the United States, extending patent protection in that patent family through 2032." (10-K for fiscal 2025)SEC filing · Feb 26, 2026
Where it stands3 findingsFor Pro members3 findings on where RYTM stands: its cash, debt, and share count, for Pro members
What changed in its filings1 findingOne customer made up 69% of its revenue in fiscal 2025, down from 74% in fiscal 2024.SEC filing · Feb 26, 2026
Who holds and trades it3 findingsFor Pro members3 findings on who holds and trades RYTM, for Pro members
Against its closest peers3 peersNet income over four quarters: RYTM -$205M, TVTX -$43.5M, ARWR -$320M, MIRM -$860M.

8 more findings on RYTM, each with its source, for Pro membersGet in free →

How RYTM ranks in Biotech

RYTM is #96 of 291 by Quality Score.

How RYTM ranks in Biotech
1	KNSAKiniksa Pharmaceuticals International	6/14	21
2	TGTXTG Therapeutics	8/14	19
3	AMGNAmgen	5/14	19
	RVMDRevolution Medicines		Open for its score
	RXRXRecursion Pharmaceuticals		Open for its score
	SABSSAB Biotherapeutics		Open for its score
	SANASana Biotechnology		Open for its score
96	RYTMRhythm Pharmaceuticals	4/14	2

Net income over four quarters: RYTM -$205M, TVTX -$43.5M, ARWR -$320M, MIRM -$860M.

When does RYTM report earnings, and what happens after?

Reports Tue Nov 3, before the open (tomorrow). Confirmed.

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What RYTM reported on Aug 4, 2026

The quarter

The figures are not read from the release yet.

“The sequential quarter over quarter growth in U.S. revenue was driven primarily by increased patient demand for IMCIVREE in acquired HO, as well as continued growth in demand in Bardet-Biedl syndrome (BBS).”

The filing on EDGAR

Where the sales came from

RYTM's results filing gives no sales by line in a table we read.

The outlook

The outlook the company gave, by period
Measure	Figure
Year ending December 31, 2026
Non-GAAP operating expenses	about $363M to $397Mcut

Figures as filed (SEC filing, Aug 4)

In the company's words

“The year-over-year increase was primarily due to increased personnel costs, including stock-based compensation, related to expanded business operations.”

From its results filing (SEC filing · Aug 4)

The numbers

Market value: $6.4B; today
Sales: $240M; up 53.5% on the year

Its share count grew 7.6% a year over 3 years.

3 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on RYTM: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.Get in free →

-1.1%+7.9%+2.9%

Feb 26May 5Aug 4

Reported	When	Gap	Reaction	5 sessions
Aug 4, 2026Before open	Before open	-2.0%	+2.9%	+12.4%
May 5, 2026Before open	Before open	+9.7%	+7.9%	+2.1%
Feb 26, 2026Before open	Before open	+4.1%	-1.1%	-8.2%

RYTM closed higher after 2 of its last 4 reports.

All 4 reports, and RYTM's Quality Score going into each

Everyone reporting earnings this week

RYTM sales and profit by year

Sales and profit by year

Sales grew every year from 2021 to 2025, to $190M. It lost money in each of the five years.

RYTM share count over time

8% more shares than a year earlier.

Weighted shares, quarter to Jun 30, 2026, both from one filing

Shares of RYTM outstanding, as filed
Shares outstanding	As of
68.9M	Aug 1, 2026
68.5M	May 1, 2026
68.3M	Feb 24, 2026
66.7M	Oct 31, 2025

Offerings, shelves, and splits of RYTM, from its filings
From its filings	Filed
Registered shares for a later sale (S-3ASR)	Feb 26, 2026
Raised $175M in a sale of shares, about 3% of its market value	Jul 10, 2025
Set up an at-the-market program for up to $200M of shares, about 3% of its market value	Feb 29, 2024

Insiders trading RYTM

RYTM insider trades

One insider sold $428K across 1 filing in the last 6 months. No open-⁠market buys on record. The newest:

SellChristopher Paul German$428KCorporate Controller & CAOat $92.21 on May 15, filed May 19

SellChristopher Paul GermanCorporate Controller & CAO$428Kat $92.21 on May 15, filed May 19

RYTM's officers and directors

Officers and directors with a Form 4 in the last 12 months.

David P. MeekerPresident and CEO · 1 trade
Hunter C. SmithChief Financial Officer · 8 trades
Pamela J. CramerChief Human Resources Officer · 4 trades
Christopher Paul GermanCorporate Controller & CAO · 2 trades
Jennifer Kayden LeeEVP, Head of North America · 1 trade
Alastair GarfieldChief Scientific Officer · 1 trade
Joseph ShulmanChief Technical Officer · 1 trade
Yann MazabraudEVP, Head of International · 1 trade

6 more officers and directors file at RYTM. Each page above names the rest.

See insider trades by person

Which ETFs hold RYTM?

In ETFs: RYTM is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

414 employeesBoston, MArhythmtx.com

What Rhythm Pharmaceuticals says it competes with

“The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change.”

From its annual report, SEC filing · Feb 26, 2026

2 more sentences and what it says it does, for Pro membersGet in free →

RYTM's score card

Rhythm Pharmaceuticals (RYTM): Quality Score 2, Below Average, #96 of 291 in Biotech, with its price, on Breakaway — The picture a link to this page shows when it is shared.

Pro members see every line of every stock's score.

What would turn RYTM's score around: 7 things
4 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayMay 19Christopher Paul German sold RYTM$428K at $92.21, filed May 19

Alerts are optional.

See RYTM's 14 chart checks

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Straight Answers

As of Nov 2, 2026: RYTM's Quality Score is 2 (Below Average), #96 of 291 in Biotech. Insiders sold $428K in the last 6 months (Form 4).

Is RYTM a good stock to buy? What its Quality Score says

RYTM scores 2 today, which Breakaway calls Below Average. It is #96 of 291 in Biotech by Quality Score, with 4 of 14 chart checks firing. Down 17% in a year while the S&P 500 rose 12%; up 307% over three years. Cash lasts about 12 quarters at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is RYTM's Quality Score?

RYTM scores 2 today, which Breakaway calls Below Average (0 to 5). That is #96 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind RYTM's 2.

Are insiders buying RYTM?

One insider sold $428K across 1 filing in the last 6 months. No open-⁠market buys on record. The newest is Christopher Paul German, Corporate Controller & CAO, who sold $428K on May 15.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.